Omalizumab

Omalizumab
	Omalizumab structure: (A) murine complementarity-determining region and (B) IgG1κ human framework
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IgE Fc region
Clinical data
Pronunciation	/ˌoʊməˈlɪzumæb/; OH-mə-LI-zoo-mab
Trade names	Xolair
Biosimilars	Omalizumab-igec, Omlyclo
AHFS/Drugs.com	Monograph
MedlinePlus	a603031
License data	US DailyMed: Omalizumab;
Pregnancy; category	AU: B1; ;
Routes of; administration	Subcutaneous
ATC code	R03DX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	26 days
Identifiers
CAS Number	242138–07–4 ;
DrugBank	DB00043 ;
ChemSpider	none;
UNII	2P471X1Z11;
KEGG	D05251;
ChEMBL	ChEMBL1201589 ;
Chemical and physical data
Formula	C6450H9916N1714O2023S38
Molar mass	145058.53 g·mol−1
	(what is this?) (verify)

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.

Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes.

The primary adverse effect of the drug is anaphylaxis and studies are underway regarding the increased risk of patients developing cardiovascular (CV) or cerebrovascular (CBV) disease.

In 1987, Tanox filed its first patent application on the anti-IgE drug candidate. Omalizumab was approved for medical use in the United States in June 2003, and authorized in the European Union in October 2005.